Read about the latest news and developments at IDT Biologika, including the company’s growth, innovations and community involvement.
Optimized vector vaccine against corona shows good efficacy in preliminary tests. more info
Dessau-based company to now fill AstraZeneca COVID-19 vaccine - Merz Pharma is foregoing capacities at short notice more info
Overall, a total of 100 million euros are currently being invested in the site... more info
Takeda provides booked capacity at the IDT site in Dessau more info
Initial data for corona vaccine indicate good tolerability but weak immune response more info
If you are a journalist and have any questions, please don't hesitate to contact us.
Corporate Communication
Optimized vector vaccine against corona shows good efficacy in preliminary tests. more info
Dessau-based company to now fill AstraZeneca COVID-19 vaccine - Merz Pharma is foregoing capacities at short notice more info
Overall, a total of 100 million euros are currently being invested in the site... more info
Takeda provides booked capacity at the IDT site in Dessau more info
Initial data for corona vaccine indicate good tolerability but weak immune response more info
5 million vaccine doses against COVID-19 more info
IDT Biologika receives official notification of funding from the Federal government more info
Clinical phase about to begin more info
Battle against SARS-CoV-2 at the heart of Germany more info
IDT Biologika expands portfolio of viral vaccines and biologics more info
IDT Biologika Awarded new Task Order in the Scope of 10-Year NIH Contract to Manufacture Vaccines and Biologics for Infectious Diseases more info
New building for vaccine production enables even more flexible reaction to customer demands more info
Ceva completes acquisition of IDT veterinary business assets, moving closer to its 2020 objective of 50:50 bio-pharma split more info
Divestment of animal health business unit enables focus on global growth market more info
Ceva Santé Animale and IDT Biologika GmbH announce agreement for Ceva to acquire the IDT animal health business, expanding its global vaccine portfolio and boosting swine innovation more info
IDT Biologika Receives Six 2019 CMO Leadership Awards more info
IDT Biologika Awarded 10-Year NIH Contract to Manufacture Vaccines and Biologics for Infectious Diseases more info
CEPI Awards Contract Worth Up To USD$36 million to Consortium led by IDT to Develop MERS Vaccine more info
Prime Minister hails exemplary success story more info
The pharmaceuticals company intends to use this takeover to continue expanding its herd-specific vaccine business more info
IDT Biologika receives three Life Science Leader’s more info
Our new senior management team is now complete more info
Former Schade brewery grounds handed off to IDT Biologika more info
Plans to Build Out New, State-of-the-Art Vaccine Manufacturing Hub in Ontario more info
After two years of construction, IDT Biologika is celebrating the opening of its new research and development building at its Riems site in Greifswald. more info
IDT Biologika receives Life Science Leader’s 2017 CMO Leadership Award in multiple categories more info
IDT Biologika Establishes Animal Health Americas Business Unit more info
UK specialist company for autogenous vaccines to be integrated in IDT’s Global Animal Health Vaccine Network more info
IDT creates new capacities for the development of human vaccines. more info
BARDA Awards IDT Biologika Contract for Live Virus Filling and Finishing Services more info
Through their PROVEO Partnership, CMC Biologics and IDT Biologika Announce the Addition of Cerbios-Pharma and Oncotec Pharma to their Strategic Collaboration for Manufacture of Antibody Drug Conjugates more info
IDT Biologika, a globally integrated manufacturer of vaccines and biopharmaceuticals, announces today the one-year anniversary celebration of its first U.S. contract manufacturing facility in Rockville, Maryland. more info
Biologics Manufacturing Leader Will Highlight Continued Worldwide Growth of Operations to Meet Strong Demand for Vaccine and Viral Vector Therapeutics, and Pharmaceutical Development and Production. more info
Collaboration Positions IDT/Gallant as a Leader in Canadian Animal Health Market. Accelerates Development as Canada’s Only “Vaccine-Only” Animal Health Company. more info
The new building for research and quality control at IDT Riems is moving forward on schedule, with the cornerstone laid last May and the building shell completed at the start of the year. more info
An autonomous and closed site was the goal, when the ground was first broken for the IDT Biologika bypass road in April 2014. more info
CMC Biologics A/S announced the formation of a strategic collaboration to provide a complete and efficient solution for the manufacture of antibody drug conjugates (ADCs). more info
The conference rooms on the second floor of Building 211 were transformed into a press center for the event. more info
Leading-edge vaccine technologies more and more globally recognized. more info
Plenty has changed in a very short time for IDT Biologika employees in Maryland. On “Day One” they were welcomed to the IDT family and introduced to a company with a significantly different outlook from before. more info
.jpg)
Gallant Custom Laboratories in the Canadian city of Cambridge, Ontario has been “an IDT company” since September 1 of this year. more info
A new partnership has led to a new IDT location. Aeras TB has sold its contract manufacturing division to IDT. more info
The representatives of government sent a clear signal of support for the site and its development. more info
IDT Biologika, a major contract manufacturer of biopharmaceuticals and vaccines, today announced it is the recipient of the 2015 Facility of the Year Award (FOYA) for facility integration. more info
IDT Biologika, a major contract manufacturer of biopharmaceuticals and vaccines, accepted a CMO Leadership Award for quality, reliability, productivity and innovation during a ceremomy held in New York City, March 18th. more info
IDT Biologika is sharing the 2014 Hugo Junkers Innovation Award in the Applied Research category with its innovative production process for a recombinant live vaccine. more info
Based on its recent analysis of the biopharmaceutical contract manufacturing industry, Frost & Sullivan recognizes IDT Biologika with the 2014 Europe Frost & Sullivan Award for Customer Service Leadership. more info
IDT Biologika and AstraZeneca establish strategic partnership for vaccine production more info
